Cypress Shipping Fibromyalgia Drug


San Diego’s Cypress Bioscience (NASDAQ: CYPB) says in its Q1 financial results today that it began shipping its new drug milnacipran HCL (Savella) last month. The drug gained FDA approval earlier this year for treating fibromyalgia. Cypress says its first-quarter loss widened to $9.2 million from $2.9 million in the same quarter last year. The biotech has about $160.4 million in available cash.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at or call (619) 669-8788 Follow @

By posting a comment, you agree to our terms and conditions.